Yes, clascoterone (Winlevi) does avoid entering the bloodstream—and that’s precisely why it sidesteps the systemic side effects that make oral spironolactone problematic for many patients. When applied as a 1% cream, clascoterone is rapidly metabolized in the skin itself, converting to an inactive compound called cortexolone before it has any real chance of reaching systemic circulation.
Even at the maximum tested dose of 6 grams applied twice daily, serum concentrations remain negligible at just 4.5 ± 2.9 ng/mL—essentially background levels. This fundamental difference represents a significant shift in how dermatologists can treat hormonally-driven acne, especially in male patients who’ve historically avoided oral antiandrogens altogether due to feminizing side effects. This article explores how clascoterone achieves this localized mechanism, what the clinical data actually shows about systemic absorption, and how it compares directly to spironolactone.
Table of Contents
- How Does Clascoterone Stay in the Skin and Out of the Bloodstream?
- The Minimal Systemic Absorption Data and What It Means for Safety
- Comparing Clascoterone and Spironolactone: A Systemic Difference
- Clinical Evidence of Systemic Safety from FDA Trials
- The HPA Axis and Reversible Side Effects: What Actually Happened
- When Clascoterone Might Not Be the Right Choice
- The Future of Topical Antiandrogens and Emerging Data
- Conclusion
How Does Clascoterone Stay in the Skin and Out of the Bloodstream?
The answer lies in the chemistry and metabolism of the compound itself. Clascoterone is designed as a prodrug that works locally—meaning it’s activated where it needs to work (in sebaceous glands and dermal papilla cells) and then immediately deactivated before systemic absorption becomes meaningful. Once the medication penetrates the skin’s outer layers, local enzymes convert clascoterone into cortexolone, an inactive metabolite that lacks the androgen-blocking properties. This conversion happens rapidly enough that clascoterone never accumulates in circulation. Think of it like a targeted chemical reaction: clascoterone is the active form while it’s in the dermis, where it blocks androgen receptors on the cells that produce excess sebum. The moment it’s metabolized to cortexolone, it loses its power—and that inactive form doesn’t travel into the bloodstream in meaningful quantities.
This is fundamentally different from spironolactone, which is swallowed and must enter systemic circulation to work anywhere in the body. with spironolactone, you accept whole-body antiandrogenic effects to get local skin benefits. With clascoterone, you get the skin benefits without the systemic cost. The skin acts as a natural barrier and metabolic factory. most topical medications—whether steroids, retinoids, or antiandrogens—are designed to work at the surface and never accumulate systemically. Clascoterone simply takes this principle further, with its rapid local metabolism being the key to safety.
The Minimal Systemic Absorption Data and What It Means for Safety
The clinical data on systemic absorption is remarkably clear. In controlled trials measuring serum levels of clascoterone, maximum circulating concentrations reached only 4.5 ± 2.9 nanograms per milliliter—even when patients applied the cream at the highest dose (6 grams twice daily for extended periods). To put this in perspective, that’s comparable to background noise in blood chemistry. Your body naturally produces small amounts of various compounds, and clascoterone serum levels fall well within what would be considered negligible. This low absorption has a direct clinical implication: it means the dose limitation for systemic side effects is much higher than what you’d see with oral medications.
With spironolactone, every milligram you take enters systemic circulation and affects androgen receptors throughout your body—in breast tissue, in reproductive organs, in adrenal glands. With clascoterone applied topically, the vast majority of the medication never makes it to those tissues in the first place. However, there’s an important caveat: patients with severely compromised skin barriers (such as those with severe atopic dermatitis or other inflammatory skin conditions) may experience slightly higher absorption, so caution is warranted in those populations. But for the typical acne patient, the skin barrier remains an excellent protective filter. The rapid conversion to cortexolone also means that even the small amount that does reach systemic circulation is already in its inactive form. You’re not circulating clascoterone; you’re circulating cortexolone, which has no antiandrogen activity.
Comparing Clascoterone and Spironolactone: A Systemic Difference
Spironolactone and clascoterone are both androgen receptor antagonists, but they work in fundamentally different ways—and that difference has enormous implications for side effects. Clascoterone is actually significantly more potent at blocking androgen receptors in the cells that matter most for acne (sebocytes and dermal papilla cells). Yet paradoxically, systemic side effects are virtually absent with clascoterone while being relatively common with spironolactone. Here’s why: spironolactone is a systemic medication. When you take it orally, it blocks androgen receptors throughout your entire body.
In men, this can lead to gynecomastia (breast enlargement), reduced libido, and erectile dysfunction—side effects that occur precisely because the medication is everywhere in the bloodstream. women taking spironolactone may experience irregular menstrual periods or increased breast tenderness. These aren’t rare side effects; they’re part of the drug’s mechanism of action when used systemically. Clascoterone, by contrast, is never present in meaningful quantities in the blood, so it never encounters the androgen receptors in breast tissue, reproductive organs, or other systemic tissues. A male patient using clascoterone won’t develop gynecomastia because the medication simply isn’t in his circulation to affect breast tissue. This represents the first novel topical antiandrogen to receive FDA approval in 40 years—a meaningful distinction that reflects the genuine advance in drug design.
Clinical Evidence of Systemic Safety from FDA Trials
The FDA approval of clascoterone in August 2020 was based on extensive clinical data. Two randomized controlled trials enrolled 1,440 participants with moderate acne vulgaris, ranging from 9 to 58 years old. This is a notably diverse age range, including adolescents and adults, male and female participants—essentially a real-world population. After 12 weeks of treatment, patients using clascoterone experienced treatment success (defined as at least a 2-grade improvement on the Investigator’s Global Assessment scale combined with a 50% reduction in lesion count) in 18-20% of cases, compared to just 7-9% in the placebo group.
Those efficacy numbers might seem modest on their surface, but they’re significant for a topical acne medication—especially one without systemic side effects. More importantly, the safety data showed no concerning patterns. There were no reports of systemic antiandrogenic effects (the feminizing side effects seen with spironolactone in men), no unexpected hormonal changes, and no serious adverse events attributable to systemic absorption. The trial population included plenty of male participants, and none developed gynecomastia or other signs of systemic antiandrogenic activity. This safety profile held up across the age range studied, including adolescents as young as 9 years old—a population where systemic medications raise particular concerns about long-term hormonal effects.
The HPA Axis and Reversible Side Effects: What Actually Happened
There is one systemic side effect that deserves closer examination: mild HPA axis suppression. In some study subjects exposed to maximum-use conditions (6 grams applied twice daily for extended periods), mild and asymptomatic suppression of the hypothalamic-pituitary-adrenal axis was observed after 14 days of continuous maximum-dose application. This might sound alarming if you’re not familiar with what HPA suppression actually means and how it typically resolves. The crucial detail is that this suppression was reversible and resolved completely within 4 weeks of discontinuing the medication—meaning patients’ HPA function returned to normal on its own. No subject required medical intervention or experienced symptoms like fatigue or weakness. This is important context: HPA suppression sounds concerning, but when it’s mild, asymptomatic, and fully reversible within weeks, it represents a safety profile that’s actually quite reassuring.
Many topical medications (including some prescription steroids) can cause mild HPA suppression. What matters is whether it’s reversible and whether patients experience symptoms. In clascoterone trials, neither happened at any clinically meaningful level. However, there’s a practical warning here: the maximum-use conditions (6 grams twice daily) represent extreme usage. Most patients would use considerably less—perhaps 1-2 grams daily applied to affected areas only. At typical doses, HPA suppression would be even less likely to occur.
When Clascoterone Might Not Be the Right Choice
Despite its safety advantages, clascoterone isn’t appropriate for everyone, and understanding when to choose a different treatment matters. Patients with mild, non-hormonally-driven acne (acne that hasn’t responded well to antiandrogen therapy or where hormonal factors aren’t dominant) may see better results with standard topical retinoids or benzoyl peroxide. Clascoterone specifically targets androgen-driven sebaceous gland dysfunction, so it works best when that’s actually the primary problem. For a 16-year-old with mild comedonal acne on the forehead that started after a single skincare product, a retinoid might be more appropriate than an antiandrogen. There’s also a practical consideration around application and patient adherence.
Clascoterone is a cream that needs to be applied twice daily to affected areas. Some patients do better with oral medications (despite their systemic effects) because they’re easier to remember—just one daily pill. Others find twice-daily topical application burdensome, especially if they’re treating large areas like the entire face and upper back. Additionally, clascoterone’s efficacy in female patients with severe hormonal acne driven by conditions like PCOS or androgen excess may be limited compared to oral spironolactone, which achieves higher systemic antiandrogen levels. The localized approach is excellent for many women, but those with significant endocrine abnormalities might still benefit more from systemic treatment combined with endocrinologic management.
The Future of Topical Antiandrogens and Emerging Data
Clascoterone’s approval opened a new category of acne treatment, and emerging research continues to expand understanding of its applications. A Phase 3 trial called SCALP, which tested clascoterone 5% (a higher-concentration formulation called Winlevi 5) for androgenetic alopecia (male and female pattern hair loss), returned strong topline results in December 2025. Notably, that trial showed no signal of systemic hormonal side effects, even in a population being treated for a different indication with a higher concentration than the acne formulation.
This additional data point further confirms the safety profile of the compound across different concentrations and use cases. The success of clascoterone has prompted research into other topical androgen receptor antagonists and has shifted the conversation in dermatology about how to approach hormonally-driven skin conditions without accepting systemic side effects. As more data accumulates on long-term use, combination therapy (for example, clascoterone plus a retinoid), and specific patient populations, the role of topical antiandrogens in the acne treatment algorithm will likely expand. For now, clascoterone represents a genuine advance for patients—particularly men and adolescents—who benefit from antiandrogen therapy but want to avoid the systemic risks.
Conclusion
Clascoterone’s ability to remain localized in the skin while blocking androgen receptors in sebaceous glands represents a meaningful advance over systemic antiandrogens like spironolactone. The clinical evidence is clear: serum concentrations remain negligible even at maximum doses, the medication is rapidly metabolized to an inactive form, and systemic side effects (particularly the feminizing effects seen with spironolactone in men) are essentially absent. While efficacy rates of 18-20% might seem modest compared to some oral medications, this comes without the cost of gynecomastia, sexual dysfunction, or other hormonal side effects—a tradeoff that many patients find worthwhile.
The decision to choose clascoterone over spironolactone depends on individual factors: the severity and type of acne, whether systemic hormonal involvement is confirmed, patient preference for topical versus oral medication, and any personal risk factors for side effects. For many patients—especially adolescent males and young men—clascoterone offers a path to antiandrogen treatment that wouldn’t have been available or acceptable before FDA approval in 2020. Consulting with a dermatologist about whether clascoterone fits your specific acne pattern and medical history remains the essential first step.
